Isla, who lives with recessive dystrophic epidermolysis bullosa (RDEB) with her dad, Andy.

What I hope for EB research is to make what was once impossible, possible. I want a brighter future for Isla; I want a cure to happen in her lifetime.

- Andy & Isla, DEBRA Members

Contents

• Our research impact report
• Acknowledging funding from DEBRA UK
• Publications resulting from DEBRA UK funding

 

Our research impact report

Here at DEBRA UK, Andy & Isla's goals are also our goals. By downloading your own copy of the DEBRA UK Research Impact Report 2021, you can become familiar with the impact of epidermolysis bullosa (EB) on the lives of thousands of UK children, men and women as EB researchers strive to find a cure.

Discover:

• The scope of people affected by this debilitating skin disease;
• Our positive outlook on a future free from EB;
• Specialist healthcare and services available to EB patients and families;
• Commitment to quality research on behalf of EB patients and families;
• And more. 

DOWNLOAD THE 2021 REPORT

  

Acknowledging funding from DEBRA UK:

When presenting or publishing results, the funding from DEBRA UK should be acknowledged using our logo and the wording: 
‘Funding for <PI/Project> - grant number <GR0000XX> was obtained from DEBRA UK.’

The Principal Investigator should send pdf of all published papers, submitted manuscripts and conference abstracts regarding the Project to DEBRA UK throughout the grant period and for five years after the grant has ended. Publications will be listed below:

 

Publications resulting from DEBRA UK funding:

• 2024
• 2023
• 2022
• 2021
• 2020
• 2019

  

2024:

DEBRA UK Project	Scientific publication	Plain language article
Permanent gene therapy for RDEB	Topical gene editing therapeutics using lipid nanoparticles: 'gene creams' for genetic skin diseases?	'Gene creams' for genetic diseases
Permanent gene therapy for RDEB	Lipid Nanoparticles Efficiently Deliver the Base Editor ABE8e for COL7A1 Correction in Dystrophic Epidermolysis Bullosa Fibroblasts In Vitro
Skin microbiome of all EB types (2023) Wound healing in all types of EB (2023)	Genotype-phenotype correlation in Junctional Epidermolysis Bullosa: signposts to severity	Unique JEB mutations explain wide clinical variability, study shows
Understanding airway disease in JEB (2023)	Of LAMA3 and LAMB3: A novel gene therapy for epidermolysis bullosa (Commentary on work published in 2024)
Understanding airway disease in JEB (2023)	Lentiviral expression of wildtype LAMA3A restores cell adhesion in airway basal cells from children with epidermolysis bullosa	Cell and gene therapy approach shows promise for EB children
Scarring in RDEB (2023)	Gamma-Secretase Inhibitors Downregulate the Profibrotic NOTCH Signaling Pathway in Recessive Dystrophic Epidermolysis Bullosa	Blocking NOTCH signaling pathway could ease RDEB scarring: Study

  

Back to contents

2023:

DEBRA UK Project	Scientific publication	Plain language article
PEBLES RDEB symptoms study (2022)	Itch in recessive dystrophic epidermolysis bullosa: findings of PEBLES, a prospective register study	Itch is common in RDEB - available treatments don't help much
PEBLES RDEB symptoms study (2022)	Costs of UK community care for individuals with recessive dystrophic epidermolysis bullosa: Findings of the Prospective Epidermolysis Bullosa Longitudinal Evaluation Study
Wound healing in all types of EB (2023)	IgA nephropathy in adults with epidermolysis bullosa
Wound healing in all types of EB (2023)	Are existing validated severity scores for epidermolysis bullosa reflective of the burden of disease in patients with epidermolysis bullosa simplex?
Immune system involvement in RDEB (2023)	Inflammation-mediated fibroblast activation and immune dysregulation in collagen VII-deficient skin	Inflammation in RDEB may favor skin cancer growth
Wound healing in all types of EB (2023)	967 Spatiotemporal shifts of microbial communities at different stages of wound healing in epidermolysis bullosa
Wound healing in all types of EB (2023)	BG05 Artificial intelligence prediction of splice site mutation consequences in junctional epidermolysis bullosa: signposts to severity
Wound healing in all types of EB (2023)	BG06 Beyond keratin: when simplex is not so simple

 

Back to contents

2022:

DEBRA UK Project	Scientific publication	Plain language article
Immune system cells and RDEB wounds (2022)	Role of mTOR Signaling Cascade in Epidermal Morphogenesis and Skin Barrier Formation
Walking with EBS (2022)	P35: Alterations of forces applied under the feet in patients with epidermolysis bullosa simplex during gait
Walking with EBS (2022) Wound healing in all types of EB (2023)	488 Ground reaction forces (GRF) in patients with epidermolysis bullosa simplex (EBS) during walking
Spray on RDEB gene therapy (2022)	A systematic review of population-based genotype-phenotype correlations in recessive dystrophic epidermolysis bullosa (RDEB)
Spray on RDEB gene therapy (2022)	Restoring type VII collagen in skin
Cannabinoid treatment for all EB pain and itch	The C4EB study—Transvamix (10% THC / 5% CBD) to treat chronic pain in epidermolysis bullosa: A protocol for an explorative randomized, placebo controlled, and double blind intervention crossover study
Wound healing in all types of EB (2023)	Localized autosomal recessive epidermolysis bullosa simplex arising from a novel homozygous frameshift mutation in DST (BPAG1)
Wound healing in all types of EB (2023)	P17: Transitional care arrangements in epidermolysis bullosa: a prototype for wider dermatology
Wound healing in all types of EB (2023)	BG11: Scratching the ocular surface: a retrospective review of ophthalmological manifestations in epidermolysis bullosa
Wound healing in all types of EB (2023)	BG12: Cicatricial junctional epidermolysis bullosa: a forgotten subtype
Wound healing in all types of EB (2023)	LB978 High relative abundance of bacillales is associated with epidermolysis bullosa (EB) at different stages of wound healing
Wound healing in all types of EB (2023)	P33: Influencers in epidermolysis bullosa: the cutaneous microbiome

 

2021:

DEBRA UK Project	Scientific publication	Plain language article
Treating DEB itch with stem cells (2022)	Prevalence, pathophysiology and management of itch in epidermolysis bullosa
Treating DEB itch with stem cells (2022)	Transcriptomic profiling of recessive dystrophic epidermolysis bullosa wounded skin highlights drug repurposing opportunities to improve wound healing	Methotrexate might help in skin healing in RDEB, study suggests
Immune system cells and RDEB wounds (2022)	Regulation of the Wound Healing Response during Aging
Immune system cells and RDEB wounds (2022)	Mitochondrial metabolism coordinates stage-specific repair processes in macrophages during wound healing
Mouth/throat spray treatment (2022)	Low Acyl Gellan as an Excipient to Improve the Sprayability and Mucoadhesion of Iota Carrageenan in a Nasal Spray to Prevent Infection With SARS-CoV-2
Spray on RDEB gene therapy (2022)	The potential of gene therapy for recessive dystrophic epidermolysis bullosa
Repurposing anti-scarring drugs in RDEB Scarring in RDEB (2024)	Notch-ing up knowledge on molecular mechanisms of skin fibrosis: focus on the multifaceted Notch signalling pathway
Wound healing in all types of EB (2023)	Diagnosing genetic skin disease
Wound healing in all types of EB (2023)	P45: The good, the bad and the ugly: inflammation in epidermolysis bullosa wounds
Wound healing in all types of EB (2023)	BG08: JEBseq: a novel database to explore genotype–phenotype correlation in junctional epidermolysis bullosa

 

Back to contents

2020:

DEBRA UK Project	Scientific Publication	Plain language Article
Immune system cells and RDEB wounds (2022)	Glutamine Metabolism Controls Stem Cell Fate Reversibility and Long-Term Maintenance in the Hair Follicle
RDEB skin cancer (2023)	Heterogeneous addiction to transforming growth factor-beta signalling in recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell carcinoma
Wound healing in all types of EB (2023)	Epidermolysis bullosa

 

 
2019:

DEBRA UK Project	Scientific Publication	Plain language Article
Immune system cells and RDEB wounds (2022)	Epidermal mammalian target of rapamycin complex 2 controls lipid synthesis and filaggrin processing in epidermal barrier formation
Rigosertib for RDEB SSC (2022)	Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa–Associated Squamous Cell Carcinoma	Rigosertib may be effective, safe for squamous cell carcinoma in RDEB patients, study suggests

 

Back to contents

We'd love to hear from you!

We want to hear the voices of families living with EB to help us decide which research projects to fund.

If you would like to let us know your thoughts about our research or would be happy for us to contact you to ask for your opinion on what research we fund, please get involved.